Early glaucoma development post congenital cataract surgery

Article

Vigilance is required particularly in early infancy

"It is not yet clear if we can do anything to prevent the development of glaucoma in paediatric patients following congenital cataract surgery," declared Dr Allen Beck (glaucoma specialist at Emory University, Atlanta, Georgia, USA) when discussing the first year results of the study examining glaucomarelated adverse events in patients of the Infant Aphakia Treatment Study (IATS).1

Background

"IATS is a prospective, randomized study comprising two surgical approaches with congenital cataract surgery - no intraocular lens (IOL) and subsequent contact lens correction versus an IOL placed at the time of surgery," explained Dr Beck. "A protocol for these two approaches was followed for the randomized patients."

Standardized definitions for glaucoma were created within the IATS to ensure consistency. "We established standard definitions for glaucoma and glaucoma suspect. Previous studies have used differing definitions, so it is hard to compare the rates of glaucoma," added Dr Beck. "I am working with an international paediatric glaucoma group to further refine definitions and classification of paediatric glaucoma."

In addition to standardized definitions, examinations under anaesthesia were used to confirm diagnosis of patients and a standard examination protocol was employed for additional evaluations by the investigator if suspected glaucoma was noted.

Results

It was found that current surgical procedures did not prevent early development of glaucoma post congenital cataract surgery either with or without lens implantation. "It is important to note, that this paper represents the one year results," stressed Dr Beck. "Some investigators had postulated that improvements in cataract surgery or that using an IOL would reduce the number of early cases of glaucoma. Unfortunately, that is not what we found."

The results were a moderate surprise to the team. "The 1 year results showed more complications in the IOL group but no statistically significant difference on visual outcomes (again the 5 year results will be very important)," Dr Beck said. "Patient age still appears to play a role in the development of glaucoma. IATS investigators operated at a slightly older age (optimally 4–6 weeks, but a number of patients were older than that) in an effort to reduce early glaucoma cases, yet younger patient age was still a risk factor for the development of glaucoma." These odds decreased by 1.6 times every month the child aged.

It was also demonstrated that the chances of a child, with persistent foetal vasculature, developing a glaucoma-related adverse event was 3.1 times higher than those without persistent foetal vasculature.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.